Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort

Annals of Surgical Oncology

Volumn 20, Issue 10, 2013, Pages 3254-3258

  Greenup, Rachel ^a,b   Buchanan, Adam ^b   Lorizio, Wendy ^a   Rhoads, Keelia ^b   Chan, Salina ^c   Leedom, Tracey ^b   King, Robin ^b   McLennan, Jane ^c   Crawford, Beth ^c   Kelly Marcom, P ^a,b   Shelley Hwang, E ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; ASIAN; CAUCASIAN; COHORT ANALYSIS; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREVALENCE; RACE DIFFERENCE; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BRCA1 PROTEIN; BRCA2 PROTEIN; CALIFORNIA; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84883813542     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3205-1     Document Type: Article

References (15)

1. Daly MB, Axilbund JE, Buys S, et al. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Cancer Netw. 2010;8:562-94.
2. Young SR, Pilarski RT, Donenberg T, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer. 2009;9:86.
3. Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple-negative breast cancer. Clin Cancer Res. 2011;17(5):1082-9.
4. Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118:2787-95.
5. Robertson L, Hanson H, Seal S, et al. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer. 2012;106:1234-8.
6. National Comprehensive Cancer Network, NCCN Guidelines Version 2.2013. Hereditary Breast and/or Ovarian Cancer Syndrome. NCCN.org.
7. Comen E, Davids M, Kirchoff T, et al. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi women. Breast Cancer Res Treat. 2011;129:185-90.
8. Warner E, Foulkes W, Goodwin P, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst. 1999;91:1241-7.
9. Armstrong K, Calzone K, Stopfer J, et al. Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiol Biomark Prev. 2000;9:1251.
10. Hall MJ, Reid JE, Burbige LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115:2222-33.
11. Berry DA, Iversen ES, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002;20:2701-12.
12. Tai YC, Chen S, Parmigiani C, et al. Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction. Breast Cancer Res. 2008;10(2):401.
13. Kwon JS, Gutierrez-Barrera AM, Young D, et al. Expanding the criteria for BRCA mutation testing breast cancer survivors. J Clin Oncol. 2010;28:4214-20.
14. Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010;28:893-901.
15. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397-406.